Calling all sports tech startups ready to scale. Photo via Getty Images

Familiar names within Houston innovation have teamed up to launch a program for sports tech startups ready to scale.

Pokatok Labs announced five companies that make up its inaugural cohort. Pokatok is founded by Lawson Gow, founder of The Cannon; Chris Buckner, founder of Mainline; and Alex Gras, former chief commercial officer of The Cannon. (Note: Lawson Gow is the son of David Gow, the CEO of InnovationMap's parent company, Gow Media.)

The new program is targeting growing seed and series A startups across the scope of sports technology — health tech, gaming, fan experience, and more. The nine-week program is free to its cohort member and will run twice a year. Participating companies receive access to a network of organizations, advisors, investors, and subject matter experts within sports tech.

“Houston has a huge potential to emerge as a global leader in sports innovation, and the launch of this program is an important step in that direction,” says Gow, who serves as Pokatok's CEO.

The program will be housed in The Cannon Sports in 53West, which opened last year. Kate Evinger, who previously oversaw gBETA Houston's early stage accelerator, will lead Pokatok Labs as director.

“Each of the five companies are true disruptors within the global sports community. It is a privilege and an honor to be working alongside them, and we look forward to the great things to come from each '' Evinger says.

The first cohort of startups includes:

  • Detroit, Michigan-based Miro AI builds cutting-edge computer vision that analyzes images and videos to unlock athlete data. The technology has analyzed over 50 million athletes.
  • Monarc, headquartered in Dallas, has created a robotic quarterback called the Seeker. Several universities — like West Virginia University, Louisiana State University, and Washington University — have already tapped into the technology, as well as NFL professionals, including George Kittle, James White and Adrian Amos.
  • RE Cooling Tech, based in Lafayette, Louisiana, has a technology that cools and increases the performance of athletes before, during, and after physical exertion. The technology was validated in a study with The Korey Stringer Institute at the University of Connecticut showing efficacy in cooling and increased athletic performance.
  • Founded at MIT, Perch uses computer vision and machine learning to seamlessly track exercise, provide real time feedback, facilitate new types of competitions, and store the data for later analysis and progress tracking. The company has sold to more than 10 NFL teams, supporting two national championship college football teams, as well as a growing number of professional sports teams, colleges, military, high schools, performance facilities, and even individual home gyms.
  • Pennsylvania-based Reflexion is a portable neuro training service that gives athletes an edge with interactive lightboard based drills. Reflexion has raised over $4 million in venture funding to date, is used by thousands of athletes in homes and training centers, and is trusted by the likes of Under Armour, the Canadian National Soccer Team, and the Denver Nuggets.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”